Contract #HHSN272201800009I advanced bioscience laboratories, INC stability testing of CPG 7909 base award can 8470038 total $186,632.00
Ended Awarded Last action
- Contract number
- 75N93021F00001
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $196,994
Award facts
- Contract value 100% obligated
- $196,994.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $10,362 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $186,632 |
About this award
This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract, valued at $196,994.14, is a delivery order for stability testing of CPG 7909, a vaccine adjuvant. The contract does not have a set-aside designation.
ABL is a leading contract research and manufacturing organization that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The company has been awarded numerous federal contracts and grants, particularly from NIH and HHS, to advance the development of medical countermeasures for various infectious diseases and other health conditions. This contract is part of ABL's broader work in supporting preclinical and clinical development programs for the federal government.
Quick answers
Who was awarded contract 75N93021F00001?
75N93021F00001 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 14, 2021.
How much is contract 75N93021F00001 worth?
The government has obligated $196,994 on 75N93021F00001.
Is contract 75N93021F00001 an order under another contract?
Yes. 75N93021F00001 is a delivery order under 75N93018D00009, an indefinite delivery contract.
Was contract 75N93021F00001 competed?
The extent of competition for 75N93021F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award